Associations thérapeutiques dans la prise en charge des hépatites chroniques B

[1]  E. Schiff,et al.  A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[2]  K. Yuen,et al.  96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. , 2008, Journal of hepatology.

[3]  S. Zeuzem,et al.  Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. , 2008, Journal of hepatology.

[4]  Angeline Bartholomeusz,et al.  Antiviral drug‐resistant HBV: Standardization of nomenclature and assays and recommendations for management , 2007, Hepatology.

[5]  M. Levrero,et al.  [502] ADEFOVIR AND LAMIVUDINE COMBINATION THERAPY IS SUPERIOR TO ADEFOVIR MONOTHERAPY FOR LAMIVUDINE-RESISTANT PATIENTS WITH HBeAg-NEGATIVE CHRONIC HEPATITIS B , 2007 .

[6]  F. Zoulim,et al.  In Vitro Activity of 2,4-Diamino-6-[2-(Phosphonomethoxy)Ethoxy]-Pyrimidine against Multidrug-Resistant Hepatitis B Virus Mutants , 2007, Antimicrobial Agents and Chemotherapy.

[7]  J. Villeneuve,et al.  Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. , 2007, Journal of hepatology.

[8]  C. Mazzucco,et al.  Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present , 2006, Antimicrobial Agents and Chemotherapy.

[9]  George Kitis,et al.  Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. , 2006, Gastroenterology.

[10]  F. Zoulim.  Hepatitis B virus resistance to entecavir in nucleoside naïve patients: Does it exist? , 2006, Hepatology.

[11]  J. Villeneuve,et al.  Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. , 2006, Gastroenterology.

[12]  S. Yu,et al.  Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil , 2006, Gut.

[13]  Y. Liu,et al.  Evolution of multi‐drug resistant hepatitis B virus during sequential therapy , 2006, Hepatology.

[14]  F. Zoulim.  Antiviral therapy of chronic hepatitis B. , 2006, Antiviral research.

[15]  T. Berg,et al.  Tenofovir for patients with lamivudine‐resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy , 2006, Hepatology.

[16]  E. Schiff,et al.  A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[17]  Chien-Jen Chen,et al.  Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. , 2006, Gastroenterology.

[18]  J. Marrero,et al.  Virologic response and resistance to adefovir in patients with chronic hepatitis B. , 2006, Journal of hepatology.

[19]  Guan-Tarn Huang,et al.  Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. , 2006, JAMA.

[20]  S. Zeuzem,et al.  Telbivudine Globe Trial: Maximal Early HBV Suppression is Predictive of Optimal Two-year Efficacy in Nucleoside-treated Hepatitis B Patients , 2006 .

[21]  S. Litwin,et al.  The competing roles of virus replication and hepatocyte death rates in the emergence of drug-resistant mutants: theoretical considerations. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[22]  P. Lampertico,et al.  Adefovir rapidly suppresses hepatitis B in HBeAg‐negative patients developing genotypic resistance to lamivudine , 2005, Hepatology.

[23]  J. Marrero,et al.  Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. , 2005, Journal of hepatology.

[24]  N. Leung,et al.  A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. , 2005, Gastroenterology.

[25]  Huiling Yang,et al.  Cross-Resistance Testing of Next-Generation Nucleoside and Nucleotide Analogues against Lamivudine-Resistant HBV , 2005, Antiviral therapy.

[26]  Thomas Berg,et al.  Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. , 2005, The New England journal of medicine.

[27]  A. Valleron,et al.  Long-term hepatitis B virus dynamics in HIV–hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate , 2005, AIDS.

[28]  J. Villeneuve,et al.  Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir , 2005, Hepatology.

[29]  F. Zoulim.  New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. , 2005, Journal of hepatology.

[30]  G. Gerken,et al.  Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial , 2005, The Lancet.

[31]  F. Zoulim,et al.  A new strategy for studying In Vitro the drug susceptibility of clinical isolates of human hepatitis B virus , 2004, Hepatology.

[32]  J. Molina,et al.  Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  F. Zoulim.  Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. , 2004, Antiviral research.

[34]  P. Marcellin,et al.  Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. , 2004, The New England journal of medicine.

[35]  P. Angus,et al.  Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine , 2004, Antimicrobial Agents and Chemotherapy.

[36]  C. Gibbs,et al.  Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. , 2004, Gastroenterology.

[37]  D. Cooper,et al.  Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. , 2004, The Journal of infectious diseases.

[38]  J. Summers,et al.  Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[39]  C. Gibbs,et al.  Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. , 2003, Journal of hepatology.

[40]  M. Wulfsohn,et al.  Adefovir dipivoxil therapy for lamivudine‐resistant hepatitis B in pre– and post–liver transplantation patients , 2003, Hepatology.

[41]  A. Bertoletti,et al.  Translation of immunological knowledge into better treatments of chronic hepatitis B. , 2003, Journal of hepatology.

[42]  R. Tubiana,et al.  Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. , 2003, New England Journal of Medicine.

[43]  F. Zoulim,et al.  Inhibitory activity of dioxolane purine analogs on wild‐type and lamivudine‐resistant mutants of hepadnaviruses , 2002, Hepatology.

[44]  Chien-Jen Chen,et al.  Hepatitis B e antigen and the risk of hepatocellular carcinoma. , 2002, The New England journal of medicine.

[45]  B. McMahon,et al.  Chronic hepatitis B , 2001, Hepatology.

[46]  M. Yuen,et al.  Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy , 2001, Hepatology.

[47]  N. Terrault,et al.  Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: A comparative study using a matched, untreated cohort , 2001, Hepatology.

[48]  H. Kumada,et al.  [Chronic hepatitis B]. , 2001, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology.

[49]  E. Schiff,et al.  A multicenter United States—Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B , 2001, Hepatology.

[50]  J. Villeneuve,et al.  Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B , 2000, Hepatology.

[51]  C. Katlama,et al.  Long‐term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus–infected patients , 1999, Hepatology.

[52]  E. Schiff,et al.  Multicenter study of lamivudine therapy for hepatitis B after liver transplantation , 1999, Hepatology.